5-Carboxamido-4-amino-3-isoxazolidone, and asparagine analogue.
trans-Aziridine-2,3-dicarboxylic ester was used to prepare the required beta-chlorohydroxamic acid used in the synthesis of the title compound. The trans configuration of the asparagine analogue was established by hydrogenolysis to erythro-beta-hydroxyasparagine amide. Neither the title compound nor the intermediate aziridinehydroxamic acid (8) showed significant activity against the L1210 and P-388 tumors. The title compound was inactive as an inhibitor of asparagine synthetase from Novikoff hepatoma and did not inhibit the growth of some 25 bacteria and fungi.
D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000627:therapeutic use; D001217:Aspartate-Ammonia Ligase / Q000037:antagonists & inhibitors; D006528:Carcinoma, Hepatocellular / Q000201:enzymology; D007555:Isoxazoles / Q000138:chemical synthesis* / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D007942:Leukemia, Experimental / Q000188:drug therapy; D008113:Liver Neoplasms / Q000201:enzymology; D051379:Mice; D009374:Neoplasms, Experimental / Q000201:enzymology; D010080:Oxazoles / Q000138:chemical synthesis*; D023303:Oxazolidinones
D000970:Antineoplastic Agents; D007555:Isoxazoles; D010080:Oxazoles; D023303:Oxazolidinones; C017106:5-carboxamido-4-amino-3-isoxazolidone; D001217:Aspartate-Ammonia Ligase